Abstract
Huntington disease (HD) is one of the most common repeat expansion disorders. Clinically, HD patients exhibit considerable visit-to-visit variability in symptoms and signs independent of measuring method or rater, yet neither the precise nature nor the determinants of this clinical variability are known. Leveraging detailed genetic and longitudinal clinical data from large cohorts of HD patients, this work 1) establishes within-individual variability in disease expression as an integral part of HD semiology, demonstrating that it increases with disease duration, mutation size, younger age-at-onset, and lower body weight, 2) provides a mathematical framework linking higher phenotypic variability to increased predictive entropy, revealing a fundamental relation between within-individual variability and energy expenditure, and 3) identifies novel genetic modifiers of both within-individual variability and age-at-onset in HD. Thus, accounting for within-individual variability in HD could facilitate the discovery of pathogenic mechanisms and outcomes directly relevant to the development of disease modifying therapies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The author is partly supported by a European Research Council Starting Grant (Number: 101041677).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Data used in this work was generously provided by the participants in the Enroll-HD study and made available by CHDI Foundation, Inc. Enroll-HD is a global clinical research platform intended to accelerate progress towards therapeutics for Huntington's disease; core datasets are collected annually on all research participants as part of this multi-center longitudinal observational study (enroll-hd.org). Enroll-HD is sponsored by CHDI Foundation, Inc. Data used in this work was generously provided by the combined efforts of the Genetic Modifiers of Huntington's Disease (GeM-HD) Consortium (dbGaP accession number phs000371).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Competing Interests: The author reports no competing interests relevant to the manuscript.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.